Novo Nordisk stock trades up as new Wegovy high-dose data released

Traders Union
All News
Financial News
Novo Nordisk up 1.25% as rally continues

Highlights

Novo Nordisk reported Q1 2026 sales growth of 32% to DKK 96.8 billion, driven by strong demand and new Wegovy data.
Despite missing EPS forecasts and lower realized prices, Novo Nordisk exceeded revenue expectations and strengthened shareholder returns with nearly DKK 38 billion in buybacks and dividends.
Novo Nordisk shares show strong short-term technical momentum, but persistent overbought signals and resistance suggest a likely consolidation between $45.00 and $48.50.

Revenue outperformance and R&D focus offset missed forecasts and price declines

Novo Nordisk has released new data supporting the case for a higher dose version of its obesity treatment Wegovy, reinforcing the company's potential to capture additional market share in the fast-growing obesity segment. First-quarter 2026 sales rose by 32% to DKK 96.8 billion, aided by a favorable provision reversal in the U.S., while nearly DKK 38 billion was returned to shareholders through dividends and buybacks, reflecting strong capital management. Despite missing earnings forecasts and experiencing a 4% decline in adjusted sales at constant exchange rates due to lower realized prices, the company exceeded revenue expectations and continued to invest heavily in research and development to support future growth.

Overbought technicals emerge as momentum indicators signal upside

On the technical front, NVO is positioned above the SMA-20 at $42.50 and the SMA-50 at $39.51 but still below the SMA-200 at $49.31. The Ichimoku Kijun on the daily chart sits at $41.88, acting as immediate support. Momentum is strong, with both MACD and ADX signaling Buy, while the Awesome Oscillator also favors upside momentum. Oscillators are deep in overbought territory: RSI is elevated at 76.66, Stoch RSI is at 100, and CCI also reads overbought. BBP stands at 2.80, highlighting significant intraday buyer strength, though the prevalence of overbought signals across multiple indicators suggests conditions may be stretched in the short term.

Limited upside ahead as weekly momentum turns bearish

Over the coming week, NVO is expected to fluctuate within a typical volatility band between $45.00 and $48.50, staying within 5% of current levels. Given that weekly moving averages (MA-50, MA-100, MA-200) all generate Sell signals and momentum indicators on the weekly timeframe are mostly bearish except for a Buy reading on RSI, the scenario for further upside appears limited. Most likely, price will consolidate sideways as overbought pressures resolve. A decisive move through $48.50 would open room for continued gains, while a drop below $45.00 could trigger further declines as momentum fades.

Anton Kharitonov, expert at Traders Union, sees strong momentum in Novo Nordisk after new data on higher dose Wegovy, but warns that fundamentals are mixed. He notes heavy shareholder payouts and robust revenue, countered by an earnings miss and signs of pricing pressure. Technical indicators show the stock is overbought, limiting scope for further upside near term. "Until NVO clears $48.50, I remain cautious — short-term risk of consolidation or retracement is high."

Earlier, analysts noted that while Novo Nordisk maintained strong momentum, overbought technical conditions pointed to a heightened risk of near-term consolidation. With fresh sales growth data and persistent overbought signals now reinforcing these cautionary flags, traders should watch for potential volatility around key inflection points as consolidation remains the prevailing scenario.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.